Credit Suisse’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Credit Suisse’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-244	Closed	–	–	4476
2022 Q2	$0	Buy	+244	New	+$118	﹤0.01%	4543

Other funds holding MTCR

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Credit Suisse's MTCR Position: Q3 2022 in Review

Credit Suisse sold out of Metacrine, Inc. Common Stock (MTCR) in Q3 2022, closing a stake of 244 shares.

Credit Suisse first reported a position in MTCR in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 27 funds tracked by Wall St. Rank hold MTCR as of Q3 2022.

Credit Suisse reported no remaining Metacrine, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Credit Suisse sold 244 Metacrine, Inc. Common Stock shares in Q3 2022.
Credit Suisse first reported a position in Metacrine, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Credit Suisse's Metacrine, Inc. Common Stock position peaked at $0 in Q2 2022.
27 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.